Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Public ClinicalTrials.gov record NCT02336165. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)
Study identification
- NCT ID
- NCT02336165
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Biological
- Durvalumab Drug
- Standard radiotherapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2015
- Primary completion
- Oct 31, 2018
- Completion
- Jul 5, 2021
- Last update posted
- Oct 11, 2022
2015 – 2021
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Facility | Los Angeles | California | 90095 | — |
| Research Facility | San Francisco | California | 94143 | — |
| Research Facility | Baltimore | Maryland | 21287 | — |
| Research Facility | Boston | Massachusetts | 02114 | — |
| Research Facility | Boston | Massachusetts | 02215 | — |
| Research Facility | St Louis | Missouri | 63110 | — |
| Research Facility | New York | New York | 10065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02336165, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2022 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02336165 live on ClinicalTrials.gov.